Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Total Current Liabilities: 2009-2025

Historic Total Current Liabilities for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Sep 2025 value amounting to $24.3 million.

  • Cumberland Pharmaceuticals' Total Current Liabilities fell 21.80% to $24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.3 million, marking a year-over-year decrease of 21.80%. This contributed to the annual value of $31.6 million for FY2024, which is 13.01% up from last year.
  • As of Q3 2025, Cumberland Pharmaceuticals' Total Current Liabilities stood at $24.3 million, which was up 1.41% from $24.0 million recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Total Current Liabilities registered a high of $31.6 million during Q4 2024, and its lowest value of $17.9 million during Q3 2021.
  • Over the past 3 years, Cumberland Pharmaceuticals' median Total Current Liabilities value was $26.4 million (recorded in 2024), while the average stood at $26.9 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first decreased by 25.03% in 2021, then skyrocketed by 48.24% in 2022.
  • Over the past 5 years, Cumberland Pharmaceuticals' Total Current Liabilities (Quarterly) stood at $19.3 million in 2021, then skyrocketed by 48.24% to $28.6 million in 2022, then declined by 2.09% to $28.0 million in 2023, then rose by 13.01% to $31.6 million in 2024, then dropped by 21.80% to $24.3 million in 2025.
  • Its last three reported values are $24.3 million in Q3 2025, $24.0 million for Q2 2025, and $25.5 million during Q1 2025.